Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Jan;51(1):103-5.
doi: 10.1046/j.1365-2125.2001.01325.x.

Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations

P T Daley-Yates  1 , R C Baker
Affiliations
Clinical Trial

Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations

P T Daley-Yates et al. Br J Clin Pharmacol. 2001 Jan.

Abstract

Aims: To measure and compare the systemic bioavailability of fluticasone propionate aqueous nasal spray and a new nasal drop formulation, using a sensitive analytical method and high dose regimen.

Methods: Volunteers received four 800 microg doses of fluticasone propionate as a nasal spray or drops over 2 days, separated by an 8 h dose interval. On day 2, blood samples were collected for assay of fluticasone propionate plasma concentrations.

Results: The mean systemic exposure, for both formulations was 8.5 pg x ml(-1) x h (drops) and 67.5 pg x ml(-1) x h (spray). Mean absolute bioavailabilities were estimated to be 0.06% (drops) and 0.51% (spray), by reference to historical intravenous data.

Conclusions: Both formulations exhibited low systemic bioavailability, even at 12 times the normal daily dose. The bioavailability from the nasal drops was approximately eight times lower than from the nasal spray.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Individual plasma concentrations of fluticasone propionate in 12 healthy subjects under approximate steady-state conditions during an 8 h dosing interval following (a) 800 µg tds fluticasone propionate aqueous nasal spray or (b) 800 µg tds fluticasone propionate nasal drops. (c) Plasma AUC and absolute bioavailability (F) of intranasal fluticasone propionate relative to intravenous administration and in comparison with oral inhalation (normalized to 800 µg doses, n = 12).
See this image and copyright information in PMC

Comment in

References

    1. McDowell JE, Mackie AE, Ventresca GP, Bye A. Pharmacokinetics and bioavailability of intra-nasal fluticasone in humans. Clin Drug Invest. 1997;1:103–105.
    1. Harding SM. The human pharmacology of fluticasone propionate. Respir Med. 1990;84(Suppl A):25–29. - PubMed
    1. Callejas SL, Biddlecombe RA, Jones AE, Joyce KB, Pereira AI, Pleasance S. Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr B, Biomed Sci Applications. 1998;718:243–250. - PubMed
    1. Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1996;41:539–542. - PMC - PubMed
    1. Hardy JG, Lee SW, Wilson CG. Intra-nasal drug delivery by sprays and drops. J Pharm Pharmacol. 1985;37:294–297. - PubMed

Publication types